Premium
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B‐cell lymphoma: a Swedish lymphoma register study
Author(s) -
Wästerlid T.,
Mohammadi M.,
Smedby K. E.,
Glimelius I.,
Jerkeman M.,
Bottai M.,
Eloranta S.
Publication year - 2019
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/joim.12849
Subject(s) - comorbidity , medicine , diffuse large b cell lymphoma , lymphoma , relative risk , cancer , confidence interval
Background Comorbidity impacts overall survival amongst patients with diffuse large B‐cell lymphoma ( DLBCL ). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma‐specific mortality are less well known. Objective To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. Methods We identified 3905 adult patients diagnosed with DLBCL 2007–2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index ( CCI ). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. Results Overall, 45% of the patients ( n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of ≥2. The relative probability of presenting with poor performance status ( PS > 2) was higher amongst comorbid patients [Relative Risk Ratio ( RRR ) PS >2 : 2.02, 95% CI : 1.63–2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment ( RRR : 0.48, 95% CI : 0.38–0.61). Amongst all patients, CCI ≥ 1 was associated with a significantly increased risk of all‐cause and lymphoma‐specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all‐cause death ( HR CCI >1 : 1.54, 95% CI : 1.32–1.80), but not with lymphoma‐specific death ( HR CCI >1 : 1.05, 95% CI : 0.86–1.28). Conclusion Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.